ClinicalTrials.gg
RecruitingNCT06973928JawChildUpdated Sep 30, 2026

Is Change in Mouth Opening Related to Change in Quality of Life in Children With Type 1 Obstructive Sleep Apnea After Adenotonsillectomy?

An observational study in Sleep Apnea, Obstructive, sponsored by Groupe Adène. Recruiting at 1 site in France. Open to participants aged 3 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Groupe Adène · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.
Updated Sep 30, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
50
Ages
3 Years to 7 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 201 studies in Sleep Apnea, Obstructive with a site in France — 39 open to participants now, 48 under way, 4 of them phase 3. Sleep Apnea, Obstructive · France.

Planned enrollment
52nd of 67
50 · median 140
Started
2025
with 12 others
Observational
67 of 201
18 open now
Primary completion
2027-10
later than 29 of 47 live
Registered
181st of 201
by date

Among the 201 studies in Sleep Apnea, Obstructive with a site in France, this one is the 52nd largest by planned enrollment of the 67 observational ones that give a count, is one of 13 that started in 2025, is one of 67 observational ones, reaches primary completion later than 29 of the 47 other live ones, and was the 181st registered.

Sleep Apnea, Obstructive

2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

39 of the 201 studies in Sleep Apnea, Obstructive with a site in France are open now. Recruiting first, the newest first:

33 more — sign in →

All 39 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.

This study: 3 Years to 7 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 201 studies in Sleep Apnea, Obstructive with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if changes in quality of life are linked to changes in mouth opening after adenotonsillectomy in a group of children who were diagnosed with Type 1 Obstructive Sleep Apnea (OSA1). The main questions it aims to answer are:

Primary Objective:

•Are changes in quality of life linked to improvements in mouth opening after adenotonsillectomy?

Secondary Objectives:

  • How does quality of life change after adenotonsillectomy, based on different questionnaires about the child's sleep, breathing, behavior, and emotions?
  • Is there a link between changes in quality of life and changes in mouth movements after adenotonsillectomy?
  • Is there a link between changes in quality of life and changes in sleep quality after adenotonsillectomy?
  • How do clinical symptoms change after adenotonsillectomy?
  • Are measures of mouth movements linked to measurements of sleep quality after adenotonsillectomy?

Participation will require:

  • Participating children will have adenotonsillectomy surgery, as suggested by their doctor
  • Before and after tonsillectomy, parents of participating children will answer questionnaires related to their child's quality of life and their child's symptoms related to sleep, breathing, behavior, and emotions
  • Sleep quality and mouth opening will be evaluated in participating children before and after tonsillectomy
Read the detailed description

STUDY BACKGROUND AND OBJECTIVES Obstructive Sleep Disordered Breathing (oSDB) encompasses a range of abnormal breathing patterns during sleep, from snoring to complete airway obstruction, caused by increased upper airway resistance and pharyngeal collapsibility. Although often considered an adult disease, oSDB also occurs in children, and has been linked to metabolic, cardiovascular, and neurocognitive morbidity, and lower quality of life in pediatric patients. This study focuses on children who have Type 1 Obstructive Sleep Apnea (OSA1), a condition where a person's airway can become blocked repeatedly during sleep. The common treatment for OSA1 is adenotonsillectomy.

OSA1 is diagnosed and evaluated using the Apnea-Hypopnea Index (AHI), which is considered an indicator of OSA severity. Polysomnography (PSG), the gold standard for measuring AHI, is a time consuming and costly procedure that is impractical for follow-up in a pediatric population. Furthermore, AHI has not been shown to be related to quality of life in children with OSA1. For this reason, interest in using measuring mouth opening, instead of PSG, to evaluate OSA1 has grown. Mouth opening reflects mouth breathing, a common clinical feature of OSA1 that is linked to respiratory effort. In children with OSA1, improvements in mouth breathing have been associated with better behavior, decreased sleepiness, and increased quality of life.

The Jawac© is a novel technology that can be used to reliably measure jaw activity, which is used to evaluate mouth opening, in children. Previous research has shown that changes in respiratory effort-related arousal after adenotonsillectomy were related to changes in mandibular movement. However, no previous research has identified a straightforward, objective biomarker that correlates with quality of life and surgical outcomes in children undergoing adenotonsillectomy. Given the observed links between mouth opening, respiratory effort, and quality of life in pediatric patients, the primary objective of this clinical trial is to determine if changes in quality of life are linked to changes in mouth opening after adenotonsillectomy in a group of children who were diagnosed with OSA1. The secondary aims include studying the relationships between change in quality of life and changes in common Jawac and PSG metrics as well as evaluating variations in quality of life, changes in clinical symptoms, and the relationship between Jawac and PSG metrics in the same population of children who undergo adenotonsillectomy.

STUDY DESIGN AND METHODS This research study is non-randomized, monocentric, prospective, and features a single non-blinded arm due to its exploratory and descriptive nature. During the pre-inclusion visit (V0), surgeons will screen patients for eligibility to participate in the study. At the inclusion visit (V1), informed consent will be obtained from one parent or legal guardian of each participant, who will then complete questionnaires about their children's quality of life and sleep-related symptoms. Participating children will undergo PSG combined with Jawac measurements. The adenotonsillectomy will occur during the surgical visit (V2). Three months later, at the follow-up visit (V3), patients will again undergo PSG with Jawac measurements, and the same parent or legal guardian will complete the same questionnaires. Four months post-surgery, patients will have a follow-up consultation with the surgeon (V4). The study protocol adheres to national guidelines for standard OSA management, with the addition of the questionnaires at V1 and V3, and the PSG with Jaw activity (measured using the Jawac) measurement at V3. Only one extra consultation (V3) is added to the standard patient pathway, thus a low rate of study discontinuation is anticipated. Data from patients who discontinue or deviate from the intervention will be excluded. Adverse events will be documented throughout the study at V1, V2, V3, and V4.

03

Conditions studied

  • Sleep Apnea, Obstructive

Keywords

  • type 1 obstructive sleep apnea
  • adenotonsillectomy
  • mouth opening
  • Polysomnography
04

Who can participate

Ages eligible
3 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population will include pediatric patients between the ages of three and seven years old, who consulted with a surgeon at the study center for potential adenotonsillectomy. To be eligible to participate, patients must be beneficiaries of the French single payer national medical insurance system, be able to attend all scheduled visits and comply with trial procedures, and legal guardians must give informed consent. Full inclusion and exclusion criteria are listed in Table 1. The study center is a private French hospital that, due to the single-payer insurance system in France, should include patients from a range of socioeconomic categories and geographical (urban versus rural) locations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 3 to 7 years old
  • Received a surgical indication for adenotonsillectomy
  • Beneficiary of the French single-payer national medical insurance system
  • given
  • Able to attend all scheduled visits and comply with all trial procedures.

Exclusion criteria

Exclusion Criteria:

  • Previous adenotonsillectomy
  • Subject has already participated in the current study
  • Craniofacial malformation syndrome
  • according to age > 97th percentile
  • Previous or current stimulant medication (methylphenidate)
  • Current orthodontic treatment
  • Asymmetric score of the tonsil with a tonsil Brodsky score of ≤2
  • Subject who are in a dependency or employment with the sponsor or the investigator
  • Participation in another clinical trial or administration of an unapproved drug within the last 4 weeks before the screening date
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • All study participants

    This study is a non-randomized, monocentric, prospective trial with a non-blinded single arm. All participants need to have received a surgical indication for adenotonsillectomy to be included in the study. The participants will undergo polysomnography coupled with measurements of mouth opening (using the Jawac) before and after the adenotonsillectomy. Each participant's parent or legal guardian will also complete questionnaires that will provide information about the participant's quality of life and symptoms.

    Device: Measures of jaw activity using the Jawac

Interventions

  • DeviceMeasures of jaw activity using the Jawac

    At the inclusion visit (V1), informed consent will be obtained from one parent or legal guardian of each participant, who will then complete questionnaires about their children's quality of life and sleep-related symptoms. Participating children will undergo PSG combined with Jawac measurements of jaw activity. Patients will undergo adenotonsillectomy during the surgical visit (V2). Three months later, at the follow-up visit (V3), patients will again undergo PSG with Jawac measurements, and the same parent or legal guardian will complete the same questionnaires.

06

What researchers measure

Primary outcomes

  1. Correlation between change in quality of life and change in mouth opening

    Quality of life (QOL) will be evaluated using two versions of the Pediatric Quality of Life Inventory Parent Proxy Report (PedsQL PPR). The PedsQL PPR 2-4 will be used for participants 3-4 years old, and the PedsQL PPR 5-7 will be used for participants 5-7 years old. For both versions, total scores range from 0-100 points. Higher scores indicate better health related QOL. The JAWAC sensor will be used to measure Mouth Opening in 1/10 millimeters to assess oral breathing during sleep. Oral breathing is a potential cause of sleep apnea in children. Higher measures of Mouth Opening (in millimeters) indicates a greater degree of respiratory disturbance during sleep. The main endpoint analysis (correlation between change in QOL and change in Mouth Opening) will be done using the estimation of the ρ coefficient. A linear regression will be used for the analysis before and after adjustment for confounding variables.

    Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3).

Secondary outcomes

  1. Changes in quality of life

    QOL will be evaluated using two versions of the Pediatric Quality of Life Inventory Parent Proxy Report (PedsQL PPR). The PedsQL PPR 2-4 will be used for participants 3-4 years old, and the PedsQL PPR 5-7 will be used for participants 5-7 years old. For both versions, total scores range from 0-100 points. Higher scores indicate better health related QOL. The same parent or legal guardian will complete the PedsQL at inclusion (V1) and three months after adenotonsillectomy (V3)

    Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3).

  2. The correlations between changes in quality of life and changes in other mandibular movement metrics

    Quality of life (QOL) will be evaluated using two versions of the Pediatric Quality of Life Inventory Parent Proxy Report (PedsQL PPR). The PedsQL PPR 2-4 will be used for participants 3-4 years old, and the PedsQL PPR 5-7 will be used for participants 5-7 years old. For both versions, total scores range from 0-100 points. Higher scores indicate better health related QOL. The mandibular movement (MM) measures that will be evaluated using the Jawac are: large MM (MML): the number of MM amplitudes ≥0.3 mm from peak to peak during ≥two respiratory cycles; Sharp MM (MMS): the number of sudden large MMs (amplitude \>1mm and/or amplitude ≥200% of the previous and/or the ensuing MM amplitude) during one respiratory cycle; Mandibular movement opening (MMO): how wide the mouth opens (in mm) during MM; Time durations during non-rapid eye movement sleep when mandibular movement is higher than 0.4 mm (tMM0.4), 0.3 mm (tMM0.3), and 0.2 mm (tMM0.2). Correlation analyses will be conducted

    Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3).

  3. The relationship between changes in quality of life and changes in polysomnography respiratory disturbance index

    Quality of life (QOL) will be evaluated using two versions of the Pediatric Quality of Life Inventory Parent Proxy Report (PedsQL PPR). The PedsQL PPR 2-4 will be used for participants 3-4 years old, and the PedsQL PPR 5-7 will be used for participants 5-7 years old. For both versions, total scores range from 0-100 points. Higher scores indicate better health related QOL. Polysomnography respiratory disturbance index (PSG-RDI), which measures the number of abnormal breathing events per hour of sleep, will be evaluated as defined by the American Academy of Sleep Medicine 2018. PSG-RDI defines sleep apnea severity as follows: normal: \<5 events/hr; mild: ≥5 but \<15 events/hr; moderate: ≥15 but \<30 events/hr; severe: ≥30 events/hr. A linear regression will be used for the analysis before and after adjustment for confounding variables

    Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3).

  4. Changes in the Sleep-related Breathing Disorder scale

    Clinical symptoms will be evaluated using The Sleep-related Breathing Disorder scale of the Pediatric Sleep Questionnaire (PSQ), which consists of 22 items. The score is the mean response on non-missing items, which can vary from 0 to 1. Higher scores reflect high risk for a pediatric sleep-related breathing disorder.

    Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3).

  5. Correlations between mandibular movement and Polysomnography respiratory disturbance index

    The mandibular movement (MM) measures that will be evaluated using the Jawac are: large MM (MML): the number of MM amplitudes ≥0.3 mm from peak to peak during ≥two respiratory cycles; Sharp MM (MMS): the number of sudden large MMs (amplitude \>1mm and/or amplitude ≥200% of the previous and/or the ensuing MM amplitude) during one respiratory cycle; Mandibular movement opening (MMO): how wide the mouth opens (in mm) during MM; Time durations during non-rapid eye movement sleep when mandibular movement is higher than 0.4 mm (tMM0.4), 0.3 mm (tMM0.3), and 0.2 mm (tMM0.2). Polysomnography respiratory disturbance index (PSG-RDI), which measures the number of abnormal breathing events per hour of sleep, will be evaluated as defined by the American Academy of Sleep Medicine 2018. PSG-RDI defines sleep apnea severity as follows: normal: \<5 events/hr; mild: ≥5 but \<15 events/hr; moderate: ≥15 but \<30 events/hr; severe: ≥30 events/hr. Correlation analyses will be conducted

    Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3).

  6. Changes in acute sleep disturbances

    The Sleep Disturbance Scale for Children (SDSC) (separate versions for 3-4 and for 5-7 year olds) has 26 items, scored from 1-5 (maximmum score 130, minimum score 1). Higher scores indicate more acute sleep disturbances.

    Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3)

  7. Changes in emotional and behavioral difficulties

    The Strengths and Difficulties Questionnaire (SDQ) (separate versions for 3-4 and 5-7 year olds) has 25 items divided into 5 scales (score range: 0-40). Higher total scores suggest significant emotional and behavioral difficulties.

    Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3)

  8. Severity Hierarchy Score for Respiratory Symptoms

    The Severity Hierarchy Score (SHS) will be used to rank respiratory symptoms from least to most severe. It does not have defined maximum and minimum scores.

    Time frame: Change from the inclusion visit (V1) to three months after adenotonsillectomy (V3)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Goodman R. The Strengths and Difficulties Questionnaire: a research note. J Child Psychol Psychiatry. 1997 Jul;38(5):581-6. doi: 10.1111/j.1469-7610.1997.tb01545.x. PubMed 9255702 ↗
  • Bruni O, Ottaviano S, Guidetti V, Romoli M, Innocenzi M, Cortesi F, Giannotti F. The Sleep Disturbance Scale for Children (SDSC). Construction and validation of an instrument to evaluate sleep disturbances in childhood and adolescence. J Sleep Res. 1996 Dec;5(4):251-61. doi: 10.1111/j.1365-2869.1996.00251.x. PubMed 9065877 ↗
  • Rosen CL, Wang R, Taylor HG, Marcus CL, Katz ES, Paruthi S, Arens R, Muzumdar H, Garetz SL, Mitchell RB, Jones D, Weng J, Ellenberg S, Redline S, Chervin RD. Utility of symptoms to predict treatment outcomes in obstructive sleep apnea syndrome. Pediatrics. 2015 Mar;135(3):e662-71. doi: 10.1542/peds.2014-3099. Epub 2015 Feb 9. PubMed 25667240 ↗
  • Jordan L, Beydon N, Razanamihaja N, Garrec P, Carra MC, Fournier BP, Vi-Fane B, Kerner S, Felizardo R, Boy-Lefevre ML, De La Dure-Molla M. Translation and cross-cultural validation of the French version of the Sleep-Related Breathing Disorder scale of the Pediatric Sleep Questionnaire. Sleep Med. 2019 Jun;58:123-129. doi: 10.1016/j.sleep.2019.02.021. Epub 2019 Mar 14. PubMed 31146124 ↗
  • Chervin RD, Hedger K, Dillon JE, Pituch KJ. Pediatric sleep questionnaire (PSQ): validity and reliability of scales for sleep-disordered breathing, snoring, sleepiness, and behavioral problems. Sleep Med. 2000 Feb 1;1(1):21-32. doi: 10.1016/s1389-9457(99)00009-x. PubMed 10733617 ↗
  • Varni JW, Seid M, Kurtin PS. PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations. Med Care. 2001 Aug;39(8):800-12. doi: 10.1097/00005650-200108000-00006. PubMed 11468499 ↗
  • Aubertin G, Akkari M, Andrieux A, Colas des Francs C, Fauroux B, Franco P, Gagnadoux F, de Santerre OG, Grollemund B, Hartley S, Jaffuel D, Lafond L, Schroder CM, Schweitzer C, Charley-Monaca C. Management of obstructive sleep apnea syndrome type 1 in children and adolescents - A French consensus. Arch Pediatr. 2023 Oct;30(7):510-516. doi: 10.1016/j.arcped.2023.06.009. Epub 2023 Aug 2. PubMed 37537084 ↗
  • Costain G, Cohn RD, Malkin D. Precision Child Health: an Emerging Paradigm for Paediatric Quality and Safety. Curr Treat Options Pediatr. 2020;6(4):317-324. doi: 10.1007/s40746-020-00207-2. Epub 2020 Aug 25. PubMed 38624480 ↗
  • Martinot JB, Le-Dong NN, Denison S, Guenard HJ, Borel JC, Silkoff PE, Pepin JL, Gozal D. Persistent respiratory effort after adenotonsillectomy in children with sleep-disordered breathing. Laryngoscope. 2018 May;128(5):1230-1237. doi: 10.1002/lary.26830. Epub 2017 Aug 22. PubMed 28833232 ↗
  • Bandyopadhyay A, Slaven JE. Health outcomes associated with improvement in mouth breathing in children with OSA. Sleep Breath. 2021 Sep;25(3):1635-1639. doi: 10.1007/s11325-020-02247-2. Epub 2021 Jan 7. PubMed 33411187 ↗
  • Leal RB, Gomes MC, Granville-Garcia AF, Goes PS, de Menezes VA. Impact of breathing patterns on the quality of life of 9- to 10-year-old schoolchildren. Am J Rhinol Allergy. 2016 Sep;30(5):147-52. doi: 10.2500/ajra.2016.30.4363. PubMed 27657891 ↗
  • Liu X, Immanuel S, Pamula Y, Kennedy D, Martin J, Baumert M. Adenotonsillectomy for childhood obstructive sleep apnoea reduces thoraco-abdominal asynchrony but spontaneous apnoea-hypopnoea index normalisation does not. Eur Respir J. 2017 Jan 25;49(1):1601177. doi: 10.1183/13993003.01177-2016. Print 2017 Jan. PubMed 27811072 ↗
  • Mitchell RB, Garetz S, Moore RH, Rosen CL, Marcus CL, Katz ES, Arens R, Chervin RD, Paruthi S, Amin R, Elden L, Ellenberg SS, Redline S. The use of clinical parameters to predict obstructive sleep apnea syndrome severity in children: the Childhood Adenotonsillectomy (CHAT) study randomized clinical trial. JAMA Otolaryngol Head Neck Surg. 2015 Feb;141(2):130-6. doi: 10.1001/jamaoto.2014.3049. PubMed 25474490 ↗
  • da Silva Gusmao Cardoso T, Pompeia S, Miranda MC. Cognitive and behavioral effects of obstructive sleep apnea syndrome in children: a systematic literature review. Sleep Med. 2018 Jun;46:46-55. doi: 10.1016/j.sleep.2017.12.020. Epub 2018 Feb 9. PubMed 29773210 ↗
  • Katz ES, D'Ambrosio CM. Pathophysiology of pediatric obstructive sleep apnea. Proc Am Thorac Soc. 2008 Feb 15;5(2):253-62. doi: 10.1513/pats.200707-111MG. PubMed 18250219 ↗
  • Akkari M, Lopez R, Jaussent I, Vidal C, Skinner S, Jaffuel D, Molinari N. Is a change in mouth opening associated with improvements in quality of life in children with type 1 obstructive sleep apnoea after adenotonsillectomy? Protocol for the JawChild prospective cohort study. BMJ Open. 2025 Dec 14;15(12):e105324. doi: 10.1136/bmjopen-2025-105324. PubMed 41397757 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2027, 22 months after the start.

Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 22 months is below that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: start Oct 2025 → Dec 2025, primary completion Oct 2026 → Oct 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2025
First posted
May 15, 2025
StartActual
Dec 1, 2025was Oct 2025
Primary completionEst.
Oct 31, 2027was Oct 2026
CompletionEst.
Oct 31, 2027was Oct 2026
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
Clinique Saint Jean is now Recruiting
Sep 30, 2026
Start date
Oct 15, 2025→Dec 1, 2025 (actual)
Sep 30, 2026
Primary completion
Oct 15, 2026→Oct 31, 2027
Sep 30, 2026
Study completion
Oct 15, 2026→Oct 31, 2027
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Not yet recruiting→Recruiting
    Clinique Saint Jean is now Recruiting
    Start date Oct 15, 2025→Dec 1, 2025 (now actual)
    Primary completion Oct 15, 2026→Oct 31, 2027
    Study completion Oct 15, 2026→Oct 31, 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06973928
Lead sponsor
Groupe Adène
Collaborators
Clinique Saint Jean, France, Institute of Neurosciences of Montpellier, INSERM U583, UMR UA11INSERM-UMIDESP Institut Desbrest d'Épidémiologie et de Santé Publique, Service d'Information Médicale, Épidémiologie et Données de Santé (SIMED), CHU Montpellier, Institut National de la Santé Et de la Recherche Médicale, France
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Dec 1, 2025
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Dany Jaffuel, MD, PhD
Contact
dany.jaffuel@protonmail.com
09 71 11 79 70
Mohammed Akkari, MD
principal investigator · Clinique Saint Jean, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion